FDA Advisory Committee Votes In Favor Of Zyprexa For Two Adolescent Indications
The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted that Zyprexa(R) (olanzapine), an atypical antipsychotic, is effective and acceptably safe for the acute treatment of schizophrenia or manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.
More: continued here
Filed under: Bipolar on June 19th, 2009
You must be logged in to post a comment.